- Early Phase Clinical Research Support (EPCRS) The Early Phase Clinical Research Support (EPCRS) provides critical resources for innovative short duration research protocols at UNC Lineberger Comprehensive Cancer Center (LCCC) in the form of skilled and specialized research coordinator, data management, and laboratory support. The trials supported by this resource are: complex with strong correlative science and/or pharmacokinetic and pharmacodynamic components; LCCC investigator-initiated; and primarily based on scientific expertise and interests of LCCC members. Trials are selected from among those submitted to the Protocol Office Executive Committee for review. Dr Claire Dees, EPCRS Faculty Director and co-leader, Clinical Research Program, in direct consultation with Drs. Carey (Associate Director, Clinical Sciences) and Hayes (co-leader, Clinical Research Program), makes the final selection. LCCC members conducted numerous innovative studies over the last five years including those: evaluating novel compounds with radiation; involving novel combinations; and incorporating novel correlative biomarkers and imaging. Many ECPRS supported trials originated in basic and preclinical science in UNC Lineberger laboratories. Since 2010, LCCC recruited a number of talented investigators actively growing our Phase I investigator initiated trial portfolio and so we anticipate expanded ECPRS use. In addition, the inaugural trials of the UNC immunotherapy center will begin in this cycle and will require additional specialized support. The first patients will be enrolled on UNC immunotherapy trials in the spring of 2016 and these initial trials would include patients with acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and multiple myeloma. The strong commitment of the UNC Lineberger leadership to the development of novel therapeutics as a Cancer Center strategic direction creates an environment that will generate even greater demand for specialized support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-41
Application #
9316474
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
41
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications